Australian Clinical Labs Limited
ASX: ACL
Growth in high value genetics and oncology testing.
(Source: TradingView) 3-Month Performance Profile of ACL on a DTF compared to S&P/ASX 200 (XJO).
Australian Clinical Labs delivered a steady FY25 performance, supported by strong operational cash generation. Cash flow from operations reached $182.80 million, a 14.5% YoY increase. Core revenue expa
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
